These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 2856470)

  • 1. Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.
    Opie LH
    Cardiovasc Drugs Ther; 1987 Dec; 1(4):411-30. PubMed ID: 2856470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential antagonism by Bay k 8644, a dihydropyridine calcium agonist, of the negative inotropic effects of nifedipine, verapamil, diltiazem and manganese ions in canine ventricular muscle.
    Ishii K; Taira N; Yanagisawa T
    Br J Pharmacol; 1985 Feb; 84(2):577-84. PubMed ID: 2579702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium ions, drug action and the heart--with special reference to calcium antagonist drugs.
    Opie LH
    Pharmacol Ther; 1984; 25(3):271-95. PubMed ID: 6151199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use.
    Opie LH
    Prog Cardiovasc Dis; 1996; 38(4):273-90. PubMed ID: 8552787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies.
    Polster P; Christophe B; Van Damme M; Houlliche A; Chatelain P
    J Pharmacol Exp Ther; 1990 Nov; 255(2):593-9. PubMed ID: 1700816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.
    Opie LH
    Q J Med; 1984; 53(209):1-16. PubMed ID: 6324268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative cardiovascular actions of clentiazem, diltiazem, verapamil, nifedipine, and nimodipine in isolated rabbit tissues.
    Mecca TE; Love SD
    J Cardiovasc Pharmacol; 1992 Oct; 20(4):678-82. PubMed ID: 1280727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor effects of diltiazem, nicardipine, nifedipine and verapamil on the norepinephrine-induced contractions of the canine saphenous vein in calcium-free medium.
    Saïag B; Milon D; Bentue-Ferrer D; Allain H; Rault B; Van den Driessche J
    Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):255-69. PubMed ID: 8008975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium-channel blocking agents.
    Leonard RG; Talbert RL
    Clin Pharm; 1982; 1(1):17-33. PubMed ID: 6764159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Calcium antagonists": a class of drugs with a bright future. Part II. Determination of basic pharmacological properties.
    Spedding M; Cavero I
    Life Sci; 1984 Aug; 35(6):575-87. PubMed ID: 6087068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential cardiovascular effects of calcium channel blocking agents: potential mechanisms.
    Millard RW; Lathrop DA; Grupp G; Ashraf M; Grupp IL; Schwartz A
    Am J Cardiol; 1982 Feb; 49(3):499-506. PubMed ID: 6277175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.
    Opie LH
    Cardiovasc Drugs Ther; 1988 Mar; 1(6):625-56. PubMed ID: 3154329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.
    Millard RW; Grupp G; Grupp IL; DiSalvo J; DePover A; Schwartz A
    Circ Res; 1983 Feb; 52(2 Pt 2):I29-39. PubMed ID: 6831652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential potentiation by depolarization of the effects of calcium antagonists on contraction and Ca2+ current in guinea-pig heart.
    Okuyama R; Adachi-Akahane S; Nagao T
    Br J Pharmacol; 1994 Oct; 113(2):451-6. PubMed ID: 7834195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New advances in the field of calcium channel antagonists: cardiovascular effects and structure-activity relationships.
    Romero M; Sánchez I; Pujol MD
    Curr Med Chem Cardiovasc Hematol Agents; 2003 Jun; 1(2):113-41. PubMed ID: 15320693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial and vascular effects of efonidipine in vitro as compared with nifedipine, verapamil and diltiazem.
    Tanaka H; Masumiya H; Sekine T; Sijuku T; Sugahara M; Taniguchi H; Terada M; Saito W; Shigenobu K
    Gen Pharmacol; 1996 Apr; 27(3):451-4. PubMed ID: 8723524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excitation-contraction coupling in cardiac and vascular smooth muscle: modification by calcium-entry blockade.
    McCall D
    Circulation; 1987 Jun; 75(6 Pt 2):V3-14. PubMed ID: 2436829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological basis for use of calcium antagonists in hypertension.
    Scriabine A; Kazda S
    Magnesium; 1989; 8(5-6):253-65. PubMed ID: 2693846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of nifedipine, verapamil, and diltiazem on noradrenaline-induced contractions, adrenergic transmitter release, and alpha-adrenoceptor binding in the female rabbit urethra.
    Larsson B; Högestätt ED; Mattiasson A; Andersson KE
    Naunyn Schmiedebergs Arch Pharmacol; 1984 May; 326(1):14-21. PubMed ID: 6147759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.